Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · BAFNA PHARMACEUTICALS LTD · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
BAFNA PHARMACEUTICALS LTD is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY19–FY20 (all audited; no estimate years)
₹ crore · consolidated
FY19
FY20
Revenue
43
42
EBITDA (ex other income)
(12)
(21)
margin %
(28.4)
(50.2)
Owners' profit
(18)
0
EPS, as reported (₹)
(11.44)
(15.52)
ROE % · ROCE %
(97.3) · (31.2)
(48.3) · (47.6)
Debt / equity (x)
2.45
0.00
Cash from operations
—
—
Capex
—
—
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BAFNA PHARMACEUTICALS LTD · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 5 quarters
₹ crore
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Revenue
0
7
12
11
13
Profit before tax
0
(4)
(1)
(22)
2
Net profit
0
(2)
(1)
(22)
0
EPS (₹)
0.00
(0.90)
(0.50)
(94.39)
0.20
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BAFNA PHARMACEUTICALS LTD · 9 October 2026Page 3 of 3
Exhibit 3: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
1-day %
5-day %
26 Sept 2026 · Trading Window Closed from Oct 1 Until Q2 FY27 Results Declaration
compliance
minimal
—
—
11 Sept 2026 · Bafna Pharma 31st AGM: All 3 resolutions passed with near-unanimous support
21 Aug 2026 · 31st AGM Notice published in newspapers; AGM on September 25, 2026
compliance
minimal
—
—
19 Aug 2026 · 31st AGM on Sept 11, 2026; FY26 PAT jumps 167% to Rs.111 million
board shareholder meetings
medium
—
—
19 Aug 2026 · Bafna Pharma FY26 Annual Report: Net Profit jumps 167% to Rs.111 mn
investor communications
medium
—
—
13 Aug 2026 · Bafna Pharmaceuticals - 31st AGM on Sep 11, 2026; Book Closure Sep 5-11
board shareholder meetings
low
—
—
13 Aug 2026 · Bafna Pharmaceuticals announces 31st AGM on September 11, 2026
board shareholder meetings
low
—
—
13 Aug 2026 · 31st AGM on Sept 11, 2026; book closure Sept 5-11
board shareholder meetings
low
—
—
13 Aug 2026 · 31st AGM on Sept 11, 2026 via video conferencing; book closure Sept 5 to 11
board shareholder meetings
low
—
—
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
